Short Interest in Senti Biosciences, Inc. (NASDAQ:SNTI) Decreases By 38.7%

Senti Biosciences, Inc. (NASDAQ:SNTI) was the target of a large drop in short interest in December. As of December 31st, there was short interest totaling 1,019,881 shares, a drop of 38.7% from the December 15th total of 1,663,760 shares. Based on an average daily volume of 511,420 shares, the days-to-cover ratio is currently 2.0 days. Approximately 4.0% of the shares of the stock are sold short. Approximately 4.0% of the shares of the stock are sold short. Based on an average daily volume of 511,420 shares, the days-to-cover ratio is currently 2.0 days.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in SNTI. Citadel Advisors LLC purchased a new position in shares of Senti Biosciences during the third quarter worth $117,000. Geode Capital Management LLC lifted its stake in Senti Biosciences by 395.6% during the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after acquiring an additional 117,588 shares in the last quarter. Finally, Armistice Capital LLC purchased a new position in Senti Biosciences during the 2nd quarter valued at about $1,883,000. 25.70% of the stock is currently owned by institutional investors and hedge funds.

Senti Biosciences Trading Down 2.8%

Shares of NASDAQ:SNTI opened at $1.03 on Friday. The company has a market capitalization of $27.08 million, a price-to-earnings ratio of -0.31 and a beta of 2.13. Senti Biosciences has a 12-month low of $1.03 and a 12-month high of $5.10. The business has a 50-day moving average price of $1.50 and a 200 day moving average price of $1.67.

Senti Biosciences (NASDAQ:SNTI) last announced its earnings results on Thursday, November 13th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.10). As a group, equities research analysts predict that Senti Biosciences will post -14.54 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on SNTI. Leerink Partnrs upgraded Senti Biosciences to a “strong-buy” rating in a research report on Friday, November 21st. HC Wainwright initiated coverage on Senti Biosciences in a report on Tuesday, October 14th. They issued a “buy” rating and a $12.00 target price for the company. Chardan Capital lifted their price target on Senti Biosciences from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Wall Street Zen raised shares of Senti Biosciences to a “sell” rating in a research report on Saturday, December 13th. Finally, Leerink Partners initiated coverage on shares of Senti Biosciences in a report on Friday, November 21st. They issued an “outperform” rating and a $6.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $9.00.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.